Aspira Women's Health Appoints New CMO, Director

TL;DR

Aspira Women's Health brings in a new CMO and a new board member, signaling potential changes.

AI Summary

Aspira Women's Health Inc. announced on July 25, 2024, the appointment of Dr. Michael J. Nally as Chief Medical Officer and the election of Ms. Karen L. King to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, though specific dollar amounts for these arrangements were not detailed in this filing.

Why It Matters

The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or a renewed focus on medical innovation and governance for Aspira Women's Health.

Risk Assessment

Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts that may impact the company's future strategy and performance.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• Dr. Michael J. Nally (person) — Appointed Chief Medical Officer
• Ms. Karen L. King (person) — Elected to Board of Directors
• July 25, 2024 (date) — Date of earliest event reported

FAQ

From the Filing

0000950170-24-087276.txt : 20240729 0000950170-24-087276.hdr.sgml : 20240729 20240729160459 ACCESSION NUMBER: 0000950170-24-087276 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240725 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240729 DATE AS OF CHANGE: 20240729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241152290 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 awh-20240725.htm 8-K 8-K 0000926617 false 0000926617 2024-07-25 2024-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024     Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter)           Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)         12117 Bee Caves Road , Building III , Suite 100 , Austin , Texas   78738 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 512 ) 519-0400      Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))      Securities registered pursuant to Section 12(b) of the Act:       Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AWH Nasdaq  Capital Market  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐            Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangements of C